Latest Breaking News On - Jan wehkamp - Page 1 : vimarsana.com

Highlights from ACG 2023

Highlights from ACG 2023
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Fresenius kabiThomasf imperialeJan wehkampPaul feuerstadtEdwardv loftus jrSun pharmaFerring pharmaceuticalsTakeda pharmaceuticalsRegeneron pharmaceuticalsBoehringer ingelheimBristol myers squibbMeeting micSeres therapeuticsAvalo therapeuticsExact sciencesGossamer bio

Guselkumab Demonstrates Long-Term Benefit for Crohn Disease

During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response.

Jan wehkampAnita afzaliUc health anita afzaliUniversity of cincinnati college medicineJohnson innovative medicinesUnited european gastroenterology weekCincinnati collegeJohnson innovativeSeverely active crohnParticipants with moderatelyAchieved clinical remissionCorticosteroid free remission throughInflammatory bowel diseaseCrohn diseaseCrohn x27s disease

TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn s Disease in a Phase 2 Study

TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn s Disease in a Phase 2 Study
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of cincinnatiSpring houseBritish columbiaCraig stoltzJan wehkampAnita afzaliJanssen scientific affairsJanssen research developmentCrohn colitis foundationNeither janssen research developmentDivision of digestive diseasesExchange commissionUniversity of cincinnati college medicinePrnewswire janssen pharmaceuticals incJanssen pharmaceutical companies of johnson

Jan Wehkamp, MD: Promising New Guselkumab Data From DDW 2023

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

United statesJan wehkampJanssen research developmentDisease weekVice presidentGastroenterology disease area leaderJanssen research

New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab).

Spring houseBritish columbiaUnited statesWaqqas afifJan wehkampColitis organizationDivision of experimental medicineCrohn colitis foundationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonDepartment of medicineUniversity health centreNone of the janssen pharmaceutical companiesDivision of gastroenterologyNational institutes of health